Forum Sponsors
Please join us in thanking our sponsors for this event!
All event sponsors are either Affiliate Members or Advisory Council Members of NCBGH.
We encourage you to visit them to learn more about their services.
Platinum Sponsor


For more information, visit healthcarebluebook.com and follow us on LinkedIn Facebook Twitter
Gold Sponsors
August 7, 2023


Visit us at: apreehealth.com
August 22, 2023

In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. The Biologics License Application for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic nasopharyngeal carcinoma is currently under review by the FDA..
Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®, CIMERLI® (ranibizumab-eqrn), a biosimilar of Lucentis®, and YUSIMRY™ (adalimumab-aqvh), a biosimilar of Humira®..
Coherus is helping employers and their employees discover healthcare savings with biosimilars..
Visit www.coherus.com to learn more.
August 16, 2023


GRAIL is a healthcare company whose mission is to detect cancer early when it can be cured. GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection. Their first product, the Galleri® multi-cancer early detection test, complements guideline-recommended screenings, and can detect a cancer signal shared by more than 50 types of cancer through a routine blood draw for adults with elevated cancer risk, such as those aged 50 or older. When a cancer signal is detected, the Galleri test can predict the cancer signal origin. For important safety information visit Galleri.com/employer
August 7, 2023


Visit us on the web at:Health & Group Benefits | Retirement & Benefits | Milliman | US
August 7, 2023


Progyny is a leading fertility and family building benefits solution currently serving 390+ clients, covering 5.4M lives. Infertility impacts 1 in 8 couples and family building is expanding, with more single parents by choice and LGBTQ+ needing to use assisted reproductive technology, adoption, or surrogacy to grow their family.
Progyny works with self- and fully insured clients in the US, Canada and globally, and our services span preconception, fertility, maternity, postpartum and menopause. Our model includes clinically integrated member support with robust digital tools (virtual care, app, etc.); the largest fertility focused network of providers with ongoing management for quality; equitable and comprehensive plan coverage that includes male factor fertility coverage, adoption and surrogacy support; and integrated Rx.
All together, Progyny helps members get pregnant faster and have healthier pregnancies and babies, requiring less treatment and medication. This results in key healthcare savings for employers as well as enabling them to meet DEI goals, mental health priorities and attract/retain needs. Progyny completed its initial public offering in 2019 and trades on Nasdaq under the ticker PGNY.
Come visit us at Progyny.com